Is Century Therapeutics, Inc. (IPSC) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 24.1% / 30% | 84.6% / 30% | 0.7% / 30% | 197.4% / 5% | ✗ NOT HALAL |
| DJIM | 24.1% / 33% | 84.6% / 33% | 0.7% / 33% | 197.4% / 5% | ✗ NOT HALAL |
| MSCI | 15.2% / 33% | 53.6% / 33% | 0.4% / 33% | 197.4% / 5% | ✗ NOT HALAL |
| S&P | 24.1% / 33% | 84.6% / 33% | 0.7% / 33% | 197.4% / 5% | ✗ NOT HALAL |
| FTSE | 15.2% / 33% | 53.6% / 33% | 0.4% / 50% | 197.4% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 12.4% | |
| Operating Margin | -13.8% | |
| Net Margin | -8.8% | |
| Return on Equity (ROE) | -6.0% | |
| Return on Assets (ROA) | -3.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$104M |
| Free Cash Flow | -$105M |
| Total Debt | $44M |
| Debt-to-Equity | 27.4 |
| Current Ratio | 6.0 |
| Total Assets | $224M |
Price & Trading
| Last Close | $2.06 |
| 50-Day MA | $2.20 |
| 200-Day MA | $1.03 |
| Avg Volume | 1.8M |
| Beta | 1.7 |
|
52-Week Range
$0.34
| |
About Century Therapeutics, Inc. (IPSC)
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Century Therapeutics, Inc. (IPSC) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Century Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Century Therapeutics, Inc.'s debt ratio?
Century Therapeutics, Inc.'s debt ratio is 24.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 15.2%.
What are Century Therapeutics, Inc.'s key financial metrics?
Century Therapeutics, Inc. has a market capitalization of $363M, and revenue of $109M. The company maintains a gross margin of 12.4% and a net margin of -8.8%. Return on equity stands at -6.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.